CYP17A1 and posterior cortical atrophy: CYP17A1-targeted drugs/drug candidates have been developed over the years for the treatment of PCa, as well as Castration-Resistant PCa (CRPC) [68].CYP17A1 has emerged as an attractive target for the design of inhibitors to use as drugs against PCa [69].